SOST and osteoporosis: Sclerostin has been considered a target protein to be neutralized with IgG2 monoclonal antibodies, known as romosozumab, originally AMG785, (Amgen Inc., Thousand Oaks, CA, USA; and UCB Pharma, Brussels, Belgium), which activates Wnt signaling, thereby increasing bone formation, inhibiting bone resorption, and increasing bone mass in patients with osteoporosis [104].